German CDMO Rentschler expands biologics production capacity

Syringes and swab

German CDMO Rentschler Biotechnologie has added a new facility to its site in Laupheim, expanding its biologics capacity for the second time in a year. The company expects to add 200 jobs with the move.

The company said that it invested €24 million to add a facility with two 3,000-litre stainless steel bioreactors, more than doubling its capacity. It said that the bioreactors can be operated in parallel or staggered. They will share a downstream processing unit, which the company said will allow it to increase production while reducing costs. Rentschler said it managed to get the project completed three months ahead of schedule.

"The growing demand for biopharmaceuticals and the rising number of drug candidates in clinical development was recognized by Rentschler early on,” Frank Mathias, who became CEO in April, said in a statement. “For this reason, the company has been strategically expanding its manufacturing capacity, most recently in 2015.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Last year the German company installed a 2,000L single-use bioreactor at the site. With the expansion and anticipated growth in business, the company said it will need to hire up to 200 new employees.

With biologic drugs comprising an ever growing percent of drugmakers’ pipelines, contract manufacturers are muscling up in that category to keep pace. Last month, Somerset, NJ-based CDMO Catalent ($CTLT) said it was “aggressively growing organically” in biologics, investing $34 million in a biologics plant in Madison, WI that it opened several years ago. That outlay will add a 2/2,000-liter single-use bioreactor system, which will be capable of running either 2,000-liter or 4,000-liter batches to support late-phase clinical and commercial production.

- here’s the Rentschler release  

Related Article: 
Catalent expands biologics capacity even as it looks for M&A targets

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.